Are we optimizing gestational diabetes treatment with glyburide? The pharmacologic basis for better clinical practice
about
Oral hypoglycemic agents: do the ends justify the means?Glibenclamide, metformin, and insulin for the treatment of gestational diabetes: a systematic review and meta-analysisNifedipine pharmacokinetics are influenced by CYP3A5 genotype when used as a preterm labor tocolyticPharmacogenetics and individualizing drug treatment during pregnancy.Trends in glyburide compared with insulin use for gestational diabetes treatment in the United States, 2000-2011Pharmacokinetics of metformin during pregnancy.Maternal-fetal disposition of glyburide in pregnant mice is dependent on gestational age.Increased glyburide clearance in the pregnant mouse model.Drug metabolism and transport during pregnancy: how does drug disposition change during pregnancy and what are the mechanisms that cause such changes?Efficacy and safety of oral antidiabetic drugs in comparison to insulin in treating gestational diabetes mellitus: a meta-analysis.Gestational diabetes mellitus management with oral hypoglycemic agents.Pharmacokinetics of oseltamivir among pregnant and nonpregnant women.Identification of CYP3A7 for glyburide metabolism in human fetal livers.Clinical therapeutics in pregnancy.Contributions of human cytochrome P450 enzymes to glyburide metabolism.Expansion of a PBPK model to predict disposition in pregnant women of drugs cleared via multiple CYP enzymes, including CYP2B6, CYP2C9 and CYP2C19The impact of drug metabolizing enzyme polymorphisms on outcomes after antenatal corticosteroid use.The status of pharmacometrics in pregnancy: highlights from the 3(rd) American conference on pharmacometricsPharmacogenetics and other reasons why drugs can fail in pregnancy: higher dose or different drug?Gestational age-dependent changes in gene expression of metabolic enzymes and transporters in pregnant miceThe impact of glucocorticoid polymorphisms on markers of neonatal respiratory disease after antenatal betamethasone administration.Interpreting tacrolimus concentrations during pregnancy and postpartum.Pharmacotherapy and pregnancy: highlights from the Second International Conference for Individualized Pharmacotherapy in Pregnancy.The protective effect of glibenclamide in a model of hemorrhagic encephalopathy of prematurity.Adiponectin: are measurements clinically useful in pregnancy?Examining the Starting Dose of Glyburide in Gestational Diabetes.Obstetric Pharmacokinetic Dosing Studies are Urgently Needed.Can pregnant diabetics be treated with glyburide?Identification of the major human hepatic and placental enzymes responsible for the biotransformation of glyburide.Oral hypoglycemic agents for gestational diabetes mellitus?The human placental perfusion model: a systematic review and development of a model to predict in vivo transfer of therapeutic drugs.The use of oral hypoglycaemic agents in pregnancy.Basic obstetric pharmacology.Oseltamivir for influenza in pregnancy.Safety considerations with pharmacological treatment of gestational diabetes mellitus.Using oral agents to manage gestational diabetes: what have we learned?Comparison of glyburide with metformin in treating gestational diabetes mellitus: a systematic review and meta-analysis.Pharmacological Management of Gestational Diabetes Mellitus.Management of sulfonylurea-treated monogenic diabetes in pregnancy: implications of placental glibenclamide transfer.Pregnancy-related pharmacokinetic changes.
P2860
Q28086864-9C1A5D51-A10D-472A-8791-75FA5BA9DABFQ28255792-045B2C42-7F9C-4322-BA84-11D165245D09Q33688800-B9B30163-BB29-4DC4-BFC0-1D3C94FBB50EQ33781272-6B320BD7-2CC4-434F-8F53-D9AB163F4441Q33821627-96884A5A-E631-426B-9794-F5DF8658F262Q33861891-5B907E7B-7BD2-4748-8449-763ED29334A7Q33944036-A347F793-6F99-4E10-9249-4AC91F47C9C9Q34127908-58526A2F-383A-48CC-BA49-7ED5F7EC69E9Q34323195-4D7B892A-9F38-4409-8463-4A3563662B42Q34323577-4D1FD010-AC4B-44E3-B196-DCDD5F025A0DQ34616656-9A65DDFC-A3DF-4916-A74B-48553C24793CQ35036389-47820FCF-484E-4214-8B3B-F3B697742FFAQ35039908-3BC1121F-71AE-4DCE-B3BC-DE01ADB343E8Q35113890-AFEF43DF-AFB3-4B2C-B096-2DFB36B1C064Q35210475-69EFFE87-5430-40BD-A6C9-AF7252E36E9CQ35211432-5933E807-C995-49CB-9297-F6606173BB1EQ35923045-383DB69F-C200-4E9C-A319-50427AA69290Q36468109-06EF8903-3BDA-4F73-87EA-CB0D0266D9C7Q36562965-32241B7B-C508-43A0-BD5B-A40CF84C25F1Q36573320-82824C96-F19F-496D-8B1A-A24C844ED96EQ36641361-01D2AB5E-EF23-4FF6-8D57-A2EC09E7C185Q36799909-34C5E29B-E79B-4621-B185-6AB5743C05FFQ36810933-933836C3-6B8F-4C57-B4BB-384527FBADFDQ36825406-99DE63C8-AFE0-445B-AAD8-95DF67F09307Q36868338-D50BB3DB-8C7D-46A1-8F8E-6FBEB0D2FD97Q36904263-FF94F691-1460-487D-8B57-CBDF57772157Q37575742-D168A7D4-B5B1-4C8F-915B-CACE6F952817Q37622980-1F0E6592-28F7-44BC-BF09-88617D15F4CDQ37695883-BA89F27D-0DC9-4949-9A52-66CFAF4711CFQ37826425-50EE6592-372F-464C-AEEE-D5F38E20991CQ37874439-9B78FD49-990E-408C-AECB-1EECC231FD81Q38188053-4EDE192B-853C-498E-8DC8-540C562E1B30Q38256590-DA2A2734-E54B-4249-856E-9F703A4DE7CEQ38256591-700BC0D6-9B2F-4DF4-9D72-7467B008BB7FQ38301238-4890FE01-EE59-40E1-884E-23474F9DE1E0Q38332117-F7CC0EB6-C43B-4C68-B4B0-594E997A67A9Q38488606-6001D675-E4C4-47B6-A827-369A80B80C6FQ38597073-E9F5A56C-9769-4994-B415-0EB6581D0F2CQ38756971-527CCB3C-38AF-4B3C-971B-5A75E209C00EQ38809225-AC42C1E1-9ACE-4C6D-A8D1-AB6ACDE71FF3
P2860
Are we optimizing gestational diabetes treatment with glyburide? The pharmacologic basis for better clinical practice
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 18 March 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Are we optimizing gestational ...... s for better clinical practice
@en
Are we optimizing gestational ...... for better clinical practice.
@nl
type
label
Are we optimizing gestational ...... s for better clinical practice
@en
Are we optimizing gestational ...... for better clinical practice.
@nl
prefLabel
Are we optimizing gestational ...... s for better clinical practice
@en
Are we optimizing gestational ...... for better clinical practice.
@nl
P2093
P2860
P356
P1476
Are we optimizing gestational ...... s for better clinical practice
@en
P2093
G D V Hankins
J D Unadkat
K M Krudys
M F Hebert
M Miodovnik
P2860
P304
P356
10.1038/CLPT.2009.5
P407
P577
2009-03-18T00:00:00Z